Headinvest, LLC Eli Lilly & CO Transaction History

Headinvest, LLC

$525 Million
Q3 2024

A detailed history of Headinvest, LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Headinvest, LLC holds 698 shares of LLY stock, worth $507,585. This represents 0.12% of its overall portfolio holdings.

Number of Shares

698

Previous 703 0.71%

Holding current value

$507,585

Previous $636,000 2.83%

% of portfolio

0.12%

Previous 0.13%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$772.14 - $960.02 $3,860 - $4,800	-5 Reduced 0.71%	698 $618,000
Q2 2024 Aug 14, 2024	BUY	$724.87 - $909.04 $21,021 - $26,362	29 Added 4.3%	703 $636,000
Q1 2024 Aug 14, 2024	SELL	$592.2 - $792.28 $10,659 - $14,261	-18 Reduced 2.6%	674 $524,000
Q4 2023 Feb 12, 2024	SELL	$525.19 - $619.13 $13,129 - $15,478	-25 Reduced 3.49%	692 $403,000
Q3 2023 Dec 11, 2023	SELL	$434.7 - $599.3 $4,347 - $5,993	-10 Reduced 1.38%	717 $385,000
Q2 2023 Aug 23, 2023	SELL	$350.74 - $468.98 $51,208 - $68,471	-146 Reduced 16.72%	727 $340,000
Q1 2023 May 17, 2023	BUY	$310.63 - $364.82 $4,659 - $5,472	15 Added 1.75%	873 $299,000
Q4 2022 Feb 13, 2023	SELL	$321.55 - $374.67 $16,077 - $18,733	-50 Reduced 5.51%	858 $313,000
Q3 2022 Dec 28, 2022	SELL	$296.48 - $337.87 $29,648 - $33,787	-100 Reduced 9.92%	908 $294,000
Q2 2022 Aug 12, 2022	SELL	$278.73 - $327.27 $8,361 - $9,818	-30 Reduced 2.89%	1,008 $327,000
Q4 2021 Feb 11, 2022	SELL	$224.85 - $279.04 $7,869 - $9,766	-35 Reduced 3.26%	1,038 $287,000
Q3 2021 Nov 16, 2021	SELL	$221.6 - $272.71 $15,512 - $19,089	-70 Reduced 6.12%	1,073 $248,000
Q2 2021 Aug 30, 2021	BUY	$180.55 - $233.54 $206,368 - $266,936	1,143 New	1,143 $262,000

Others Institutions Holding LLY

# of Institutions

4,002

Shares Held

752M

Call Options Held

8.27M

Put Options Held

10.5M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $691B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Headinvest, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Headinvest, LLC with notifications on news.

Account